Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175142 | 0.88 | JMJD6 (0.50) | JMJD6ROCK2KCNK3ADAM17 | |
| SCHEMBL27918993 | 0.81 | ROCK2 (0.46) | ROCK2L3MBTL3GRM5 | |
| SCHEMBL20187358 | 0.80 | ADAM17 (0.46) | JMJD6KCNK3ADAM17 | |
| SCHEMBL164387 | 0.78 | PARP14 (0.60) | ROCK2L3MBTL3 | |
| SCHEMBL165920 | 0.77 | ROCK2 (0.48) | ROCK2L3MBTL3GRM5 | |
| SCHEMBL165005 | 0.76 | SCD (0.55) | ROCK2L3MBTL3 | |
| SCHEMBL167401 | 0.74 | ROCK2 (0.46) | ROCK2L3MBTL3 | |
| SCHEMBL166646 | 0.74 | CHRNB2 (0.50) | ROCK2KCNK3GRM5 | |
| SCHEMBL166844 | 0.74 | ALDH1A1 (0.65) | ROCK2 | |
| SCHEMBL166687 | 0.73 | CPT2 (0.50) | ROCK2L3MBTL3GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611441-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | JMJD6 2768/4885ROCK2 1674/4885KCNK3 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.